Lv3
209 积分 2020-11-23 加入
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
19天前
已完结
HCC-Live Steering Committee. BEACON-HCC: Best evidence and north american consensus on treatment allocation for hepatocellular carcinoma
19天前
已关闭
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
20天前
已完结
Multi-phase CT-based intratumoral and peritumoral radiomics for predicting tertiary lymphoid structures of hepatocellular carcinoma: a multi-center retrospective cohort study
20天前
已完结
代谢相关脂肪性肝病相关肝细胞癌诊疗进展
20天前
已完结
皖公网安备34019202002308
